Department of Medicine, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, USA.
N Engl J Med. 2011 Sep 1;365(9):815-24. doi: 10.1056/NEJMoa1104959.
Diarrhea is a frequent complication of hematopoietic stem-cell transplantation (HSCT). Important causes of diarrhea after HSCT include acute graft-versus-host disease (GVHD), infections, and medications. After the transplantation and engraftment of hematopoietic stem cells from umbilical-cord blood, we observed a new syndrome of culture-negative, antibiotic-responsive diarrhea not attributable to any known cause.
We conducted a retrospective cohort study of all patients undergoing cord-blood HSCT at our center between March 2003 and March 2010. The cord colitis syndrome was defined as a persistent diarrheal illness in such patients that was not due to acute GVHD, viral or bacterial infection, or another identifiable cause. Clinical and histopathological features of patients meeting the case definition were further analyzed.
Among 104 patients who underwent cord-blood HSCT at our center, the cord colitis syndrome developed in 11 (10.6%). The 1-year Kaplan-Meier cumulative probability of meeting the case definition for the syndrome was 0.16. The median time to onset after transplantation was 131 days (range, 88 to 314). All patients had a response to a 10-to-14-day course of empirical therapy with metronidazole, alone or in combination with a fluoroquinolone. Five of the 11 patients (45%) had recurrent diarrhea shortly after discontinuation of antibiotics, and all patients who had a relapse had a response to reinitiation of antibiotic therapy. On histologic examination, all patients with the cord colitis syndrome had chronic active colitis, with granulomatous inflammation present in 7 of 11 patients (64%).
The cord colitis syndrome is clinically and histopathologically distinct from acute GVHD and other causes of diarrhea in patients who have undergone cord-blood HSCT and is relatively common in this patient population. The syndrome should be considered in such patients who have diarrhea that is not attributable to other causes.
腹泻是造血干细胞移植(HSCT)后的常见并发症。HSCT 后腹泻的重要原因包括急性移植物抗宿主病(GVHD)、感染和药物。在脐带血造血干细胞移植和植入后,我们观察到一种新的综合征,即培养阴性、对抗生素有反应的腹泻,且无法归因于任何已知原因。
我们对 2003 年 3 月至 2010 年 3 月期间在我们中心接受脐带血 HSCT 的所有患者进行了回顾性队列研究。脐带结肠炎综合征被定义为此类患者持续存在的腹泻疾病,并非由急性 GVHD、病毒或细菌感染或其他可识别的原因引起。进一步分析符合病例定义的患者的临床和组织病理学特征。
在我们中心接受脐带血 HSCT 的 104 例患者中,11 例(10.6%)发生了脐带结肠炎综合征。该综合征符合病例定义的 1 年 Kaplan-Meier 累积概率为 0.16。移植后发病的中位时间为 131 天(范围为 88 至 314 天)。所有患者均对 10 至 14 天的经验性甲硝唑治疗有反应,单独或联合使用氟喹诺酮类药物。11 例患者中有 5 例(45%)在抗生素停药后不久出现复发性腹泻,所有复发患者对重新开始抗生素治疗均有反应。组织学检查显示,所有患有脐带结肠炎综合征的患者均患有慢性活动性结肠炎,11 例患者中有 7 例(64%)存在肉芽肿性炎症。
脐带结肠炎综合征在接受脐带血 HSCT 的患者中与急性 GVHD 和其他腹泻原因在临床上和组织病理学上均有不同,在该患者人群中较为常见。对于那些无法归因于其他原因的腹泻患者,应考虑该综合征。